Technology Partnerships
TTBE (in partnership with other technology transfer organizations) catalyzes the establishment of new technology partnerships to further develop and commercialize University (and affiliated hospital) technologies. Highlighted below are some of the commercial and pre-commercial technology partnerships established using technologies from the University of Ottawa and affiliated research institutions:
Inventor(s) |
Technology |
Status |
Year |
TTO |
|---|---|---|---|---|
Griffith |
Reconstructed Human Corneal Equivalent Model as an In-Vitro Alternative to Animal Testing |
Licensed |
|
TTBE OHRI |
|
Novel Compounds for Control of Chronic Pain |
Start-up Histogranix, Inc. |
|
TTBE |
Mussivand |
Electrohydraulic Ventricular Assist Device |
Start-up Worldheart |
1996 |
UOHI |
|
Therapeutic Peptides for Disruption of Autocrine Loops in Lung Cancer |
Panvirion Inc |
|
TTBE |
Korneluk and MacKenzie |
Development of novel therapeutic compounds that modulate the process of apoptosis |
Licensed Start-up Ægera Therapeutics Inc (formerly Apoptosis) |
1995 |
TTBE CHEO |
Krantis |
|
Licensed Start-up EnPharma |
|
TTBE |
Fliss |
Development of new therapies targeting heart disease and stroke |
Licensed Start-up Zinc Therapeutics Inc. |
|
TTBE |
Sparks |
Charge Control Technology and Lipid Carriers |
Licensed Start-up Liponex Inc. |
2000 |
UOHI |
Rudnicki et al |
Stem Cell technologies Retrofit kit for external Pre-stressing of concrete bridge columns to protect against damage from earthquakes |
Licensed Startup Stem Path Licensed Existing Company |
2003 200X |
OHRI TTBE |
The Ottawa Technology Transfer Network
Recognizing the complexity of successful technology transfer and commercialization, the University of Ottawa began working with its colleagues across the region in 1999 with the establishment of an NSERC Intellectual Property grant with Carleton University that ran until 2002.
From 2002 to 2005, TTBE worked with affiliated offices at the Ottawa Health Research Institute (OHRI) and the University of Ottawa Heart Institute as part of an NSERC-CIHR-SSHRC Intellectual Property Management grant. This liaison resulted in several collaborative technology partnerships (see table above) and the establishment of a $6M Community Based Investment Fund (CSBIF) – the Ottawa Biotechnology Fund Inc. – established in 2001 by Genesys Capital with the involvement of the Ottawa Life Sciences Council and the Institute of Biological Sciences at the National Research Council of Canada. This resulted in several investments in new ventures around university, hospital and NRC based technologies. The Ottawa Biotechnology Fund had another collaborative benefit – working with the technology transfer offices in Toronto that were dealing with another Genesys Capital CSBIF – the Discovery District Biotechnology Fund.
In March 2005 OHRI and UOHI were awarded a CIHR Intellectual Property Internship award that will involve training a recent MBA graduate in technology transfer from medical research. The new position will begin in September 2005 and run for one year. In May 2005, TTBE was awarded an Intellectual Property Mobilization grant to establish the Ottawa-Gatineau University-College Regional Innovation Alliance with Carleton University, Algonquin College and the Université du Québec en Outaouais.
TTBE is also an active member of OnSETT (the Ontario Society for Excellence in Technology Transfer), AUTM Canada (Association of University Technology Managers) and the Licensing Executive Society of Canada.
Company Research Interests
TTBE has limited information (searchable) on company research interests but has access to several databases including public information (such as Strategis) and some proprietary databases.